New Delhi : Ranbaxy Laboratories declined to comment on reports from Brussels that European Union anti-trust regulators may fine it for allegedly blocking the entry of cheaper generic medicines in the EU. Reports said that Ranbaxy was among the nine companies that are to be fined. When contacted, a Ranbaxy spokesperson said: “We will not like to offer any comments at this point”. Other firms named in the reports were Denmark’s Lundbeck, Merck KGaA, Generics UK, Arrow, Resolution Chemicals, Xellia Pharmaceuticals, Alpharma and AL Industriers. Shares of Ranbaxy fell by 3.49% to end at Rs 362.35 apiece at the BSE on Monday.
EU regulators may fine Ranbaxy and other drug makers
RECENT STORIES
Gold Prices Extend Gains For Third Consecutive Session, Rising ₹520 To ₹1,21,133 Per 10 Grams...
'SEBI Will Soon Set Up Working Group To Undertake Review Of Short Selling & Securities Lending &...
Helmet Manufacturer Studds Accessories' Shares List At 3% Discount To Issue Price Of ₹585
Regulatory Overlaps & Gaps, A Persistent Puzzle In India’s Fast-Changing Financial System
Engineering Firm Bharat Heavy Electricals Secures Order Worth ₹6,650 Crore From NTPC For Setting...